Predicting response to opiate antagonists and placebo in the treatment of pathological gambling
- 26 June 2008
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 200 (4) , 521-527
- https://doi.org/10.1007/s00213-008-1235-3
Abstract
Rationale Although opiate antagonists have shown promise in the treatment of pathological gambling (PG), individual responses vary. No studies have systematically examined predictors of medication treatment outcome in PG. Understanding clinical variables related to treatment outcome should help generate treatment algorithms for PG. Objective We sought to identify clinical variables associated with treatment outcome in PG subjects receiving opiate antagonists. Materials and methods Two hundred eighty-four subjects [137 (48.2%) women] with DSM-IV PG were treated in one of two double-blind placebo-controlled trials (16 weeks of nalmefene or 18 weeks of naltrexone). Gambling severity was assessed with the Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) with positive response defined as ≥35% reduction in PG-YBOCS score for at least 1 month by study endpoint. Depression, anxiety, and psychosocial functioning were included in stepwise logistic regression analyses designed to identify clinical factors independently associated with treatment response. Results The clinical variable most strongly associated with a positive response to an opiate antagonist was a positive family history of alcoholism (p = 0.006). Among individuals receiving higher doses of opiate antagonists (i.e., nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day), intensity of gambling urges (PG-YBOCS urge subscale) was associated with a positive response on a trend level (p = 0.036). Among individuals receiving placebo, younger age was associated, on a trend level, with positive treatment outcome (p = 0.012). Conclusions A family history of alcoholism appears to predict response to an opiate antagonist in PG. Future research is needed to identify specific factors (e.g., genetic) mediating favorable responses.Keywords
This publication has 51 references indexed in Scilit:
- The neurobiology and genetics of impulse control disorders: Relationships to drug addictionsBiochemical Pharmacology, 2008
- Individual Differences in Reward Responding Explain Placebo-Induced Expectations and EffectsNeuron, 2007
- Epidemiologic and clinical updates on impulse control disorders: a critical reviewArchiv Fur Psychiatrie Und Nervenkrankheiten, 2006
- Use of B-type natriuretic peptide in the detection of myocardial ischemiaAmerican Heart Journal, 2006
- Naltrexone in the Treatment of Alcohol DependenceNew England Journal of Medicine, 2001
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- The failure of placebo-controlled studiesEuropean Neuropsychopharmacology, 1999
- Role of opioid antagonists in treating intravenous cocaine abuseLife Sciences, 1989
- Facilitation of self-stimulation behavior following intracerebral microinjections of opioids into the ventral tegmental areaPharmacology Biochemistry and Behavior, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960